Mirex

09/01/2002 - "Finally, a tumor promotion study was conducted to determine whether E2 implants could increase the sensitivity of male mice to mirex promotion. "
11/22/2023 - "MiREx has been evaluated on four cancer primary sites from the genomics data commons (GDC) database: lung, kidney, breast, and corpus uteri. "
09/01/2002 - "E2 implants in male mice did increase sensitivity to mirex promotion; however, the implants did not produce the full female sensitivity to mirex tumor promotion. "
09/01/2002 - "17beta-estradiol is a hormonal regulator of mirex tumor promotion sensitivity in mice."
09/01/1997 - "Therefore, under these tandem conditions, tumor yields were additive, indicating that there are at least two distinct populations of mutant Ha-ras cells: one promoted by mirex and the other by TPA."

02/01/1990 - "The top dietary exposure groups of rats received the equivalent of 3.85 mg mirex/kg body weight, whereas the 100-ppm group of female rats (second study) averaged 7.7 mg/kg. At the end of the study, survival of male rats that received 25 or 50 ppm of mirex was lower than that of controls, whereas survival of all dosed groups of female rats was similar to that of controls (male: control, 44/52; 0.1 ppm, 37/52; 1 ppm, 36/52; 10 ppm, 37/52; 25 ppm, 19/52; 50 ppm, 15/52; female-- first study: 38/52; 38/52; 35/52; 41/52; 35/52; female-- second study: control, 44/52; 50 ppm, 44/52; 100 ppm, 39/52). "
02/01/1990 - "Body Weights, Feed Consumption, and Survival in Two-Year Studies: Mean body weights of male rats that received 25 or 50 ppm mirex were 5%-18% lower than those of the controls throughout most of the study; mean body weights of female rats that received 50 or 100 ppm mirex were 4%-18% lower than those of the controls after week 40; mean body weights of groups receiving 0.1, 1.0, or 10 ppm were similar to those of controls. "
02/01/1990 - "Based on feed consumption data, the estimated average intake per day was 0, 0.007, 0.075, 0.75, 1.95, and 3.85 mg mirex/kg body weight for male rats and female rats in the first study, and 0, 3.9, and 7.7 mg/kg for female rats in the additional study. "
06/01/1991 - "Pretreatment with mirex (100 mg/kg, intragastrically) increased liver/body weight ratios and DNA synthesis in livers of fed rats, effects that were markedly diminished in livers of fasted rats. "
06/01/1991 - "Mirex significantly decreased while chlordecone increased bile flow per gram liver in vivo; both compounds, however, increased bile flow when expressed per kilogram of body weight. "

09/01/1997 - "Mice treated with mirex developed a maximum of 6.4 papillomas/mouse. "
09/01/1997 - "Like 12-O-tetradecanoylphorbol-13-acetate (TPA), mirex promotes papillomas that have a Ha-ras mutation; however, unlike TPA promotion, mirex promotion does not involve a general hyperplastic response. "
09/01/1995 - "TPA- and mirex-promoted papillomas that were refractory to RA and FA demonstrated the same incidence of Ha-ras mutation as TPA- or mirex-promoted papillomas without RA and FA treatment, further indicating that the inhibitory activity of RA and FA is promoter-dependent and not solely dependent on mutant Ha-ras. "
09/01/1995 - "In contrast, mirex-promoted papilloma formation was not inhibited by either dose of RA or 0.5 nmol FA and 2 nmol FA weakly inhibited mirex-promoted papillomas by only 32%. "
01/01/1994 - "Mirex plus TPA-promoted papillomas contained a c-Ha-ras A182-->T mutation as frequently (13/14) as those promoted by mirex or TPA alone, suggesting that these DMBA-initiated/co-promoted papillomas were not atypical in this genotypic marker. "

12/01/1993 - "Multiple topical applications of mirex over a 1 month period induced only a minimal increase in the number of epidermal nucleated cell layers, which contrasts with definitive hyperplasia induced by a comparable tumor-promoting dose of 12-O-tetradecanoylphorbol-13-acetate (TPA). "
05/01/1992 - "In the intact laboratory rat, mirex induces liver growth that is an expression of both cellular hyperplasia and hypertrophy. "
05/01/1992 - "These studies suggest that the expression of hyperplasia in mirex-induced adaptive liver growth is thyroxine dependent."
09/01/1995 - "FA (2 nmol) treatment completely abolished TPA-induced epidermal hyperplasia and proliferating cell nuclear antigen (PCNA) S phase-positive cells, however, FA had no inhibitory effect on the weak proliferative response induced by mirex. "
12/01/1993 - "In liver, mirex induced biochemical responses and hyperplasia characteristic of increased cell proliferation, which is consistent with its role as a liver tumor promoter. "

11/01/1984 - "The results of this study indicate that mirex-induced postnatal cataracts are due to lens degeneration subsequent to fiber cells swelling."
11/01/1981 - "The early histologic lesions and sequential changes in the development of mirex-induced cataracts were studied in the offspring of lactating female Sherman rats given oral doses of mirex for 5 consecutive days post partum. "
06/01/1983 - "The swollen lens fibers, reduced K+/Na+ ratios and the correlation with edema suggest that fetal cataracts induced by mirex may be due to lens fiber cell breakdown subsequent to osmotic swelling."
06/01/1984 - "193, 165-175.) Plasma glucose levels were decreased by over 40% in mirex-treated fetuses which developed cataracts. "
09/01/1983 - "In contrast, incubation for 8 h in medium containing 20 microM kepone resulted in elevated lens Na+ and lower lens K+. Thus, cataracts induced by mirex in vivo are probably not due to a direct toxic effect on the lens."